- Home
- MTLS vs GOSS Comparison
MTLS vs GOSS Comparison
Compare MTLS & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- GOSS
- Stock Information
- Founded
- MTLS 1990
- GOSS 2015
- Country
- MTLS Belgium
- GOSS United States
- Employees
- MTLS N/A
- GOSS N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- GOSS Health Care
- Exchange
- MTLS Nasdaq
- GOSS Nasdaq
- Market Cap
- MTLS 349.7M
- GOSS 347.8M
- IPO Year
- MTLS 2014
- GOSS 2019
- Fundamental
- Price
- MTLS $5.13
- GOSS $2.47
- Analyst Decision
- MTLS
- GOSS Strong Buy
- Analyst Count
- MTLS 0
- GOSS 4
- Target Price
- MTLS N/A
- GOSS $8.50
- AVG Volume (30 Days)
- MTLS 127.2K
- GOSS 3.1M
- Earning Date
- MTLS 10-23-2025
- GOSS 08-05-2025
- Dividend Yield
- MTLS N/A
- GOSS N/A
- EPS Growth
- MTLS N/A
- GOSS N/A
- EPS
- MTLS 0.11
- GOSS N/A
- Revenue
- MTLS $311,850,851.00
- GOSS $40,237,000.00
- Revenue This Year
- MTLS $2.98
- GOSS N/A
- Revenue Next Year
- MTLS $7.09
- GOSS $30.65
- P/E Ratio
- MTLS $48.31
- GOSS N/A
- Revenue Growth
- MTLS 2.98
- GOSS N/A
- 52 Week Low
- MTLS $3.93
- GOSS $0.66
- 52 Week High
- MTLS $9.69
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- MTLS 47.90
- GOSS 68.08
- Support Level
- MTLS $5.01
- GOSS $2.38
- Resistance Level
- MTLS $5.32
- GOSS $2.65
- Average True Range (ATR)
- MTLS 0.18
- GOSS 0.15
- MACD
- MTLS 0.02
- GOSS 0.03
- Stochastic Oscillator
- MTLS 52.08
- GOSS 76.67
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.